-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Registration startsThe 4th GenScript Cell and Gene Therapy Industry Development and Cooperation Forum invites you to explore the road to commercialization of cell/gene therapy
September 27, 2022 Beijing
Official website: /gct-forum-2022.
html
September 27, 2022 Beijing
Official website: /gct-forum-2022.
html
FigureThe grand occasion of the GenScript Biotechnology Global Industry Forum held in San Francisco, USA in 2020: Chinese and
foreign investors, entrepreneurs in the field of cell/gene therapy, and top experts including the former director of the US FDA gathered at the forum
foreign investors, entrepreneurs in the field of cell/gene therapy, and top experts including the former director of the US FDA gathered at the forum
FigureThe grand occasion of GCT theme forums held in Shanghai and Nanjing in 2020 and 2021:
Led by 9 Chinese and foreign academicians, together with industry-university-research-funded-policy experts from all walks of life, they gathered at the grand event
Hot Topic 1: FDA Perspective - CAR-T Cell Therapy Approval Policy and Latest Regulatory TrendsFigureDr.
Peter Marks, director of the FDA Center for Biologics Evaluation and Research (CBER)
Hot Topic 2: Looking at the road to profitability of innovative drugs from the perspective of GCT commercialization Hot Topic 3: How "high-priced drugs" can benefit more patients, and payment model innovation is imminent Free registration deadline is July 31.Peter Marks, director of the FDA Center for Biologics Evaluation and Research (CBER)
com/s/UbuQZjs/# event@genscript.
com